Several earlier studies, such as those by Osako et al. [194], Kruszewski et al. [195], and Kavanagh et al. [196], reported HER2 expression rates ranging from 1.8% to 70% in CRC patients. This evidence concerns the gene ERBB2 and colorectal carcinoma.